Rheumatoid Arthritis Overview
Rheumatoid Arthritis (RA) is an autoimmune disorder of the joints characterized by inflammatory arthritis as well as extra-articular involvement. It commonly involves multiple joints of both hands with morning stiffness that may last for several hours.
“Rheumatoid Arthritis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.
The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report:
Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years. Rheumatoid Arthritis Key players such as – Landos Biopharma, OncoOne, zeta Protein-based vaccine: The University of Toledo, I-Mab Biopharma Co. Ltd., Beijing University of Chinese Medicine, Teijin Pharma, Hemay Pharmaceutical, SynAct Pharma Aps, Alexandria University, R-Pharm, Mabion, GlaxoSmithKline, and others, are developing therapies for the Rheumatoid Arthritis treatment
Rheumatoid Arthritis Emerging therapies such as – LABP-69, ON 104, 14-3-3, TJ003234, Guizhi Shaoyao Zhimu Decoction, TCK-276, ABX464: Abivax S.A., Hemay007, AP1189, Trivalent Chromium, Olokizumab, MabionCD20, Otilimab, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years.
In February 2022, XcimzaneTM, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA®, is a proposed biosimilar that has been developed, manufactured, and commercialised by Biogen Inc. and Xbrane Biopharma AB (certolizumab pegol).
In May October 2022, Alexandria University initiated a Phase II/III trial to evaluate the efficacy of trivalent chromium supplementation in rheumatoid arthritis treatment and measuring the outcomes of that in rheumatoid arthritis patients
On 3 June 2020, the Russian Ministry of Health included R-Farm’s new drug, Artlegia (olokizumab), to its COVID-19 Prevention, Diagnosis, and Treatment Provisional Guidelines. Artlegia is the first Russian original drug included to the guidelines of the Russian Ministry of Health.
Route of Administration
Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type
Products have been categorized under various Molecule types, such as
Oligonucleotide
Peptide
Small molecule
Rheumatoid Arthritis Pipeline Therapeutics Assessment
Rheumatoid Arthritis Assessment by Product Type
Rheumatoid Arthritis By Stage and Product Type
Rheumatoid Arthritis Assessment by Route of Administration
Rheumatoid Arthritis By Stage and Route of Administration
Rheumatoid Arthritis Assessment by Molecule Type
Rheumatoid Arthritis by Stage and Molecule Type
DelveInsight’s Rheumatoid Arthritis Report covers around products under different phases of clinical development like-
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Some of the key companies in the Rheumatoid Arthritis Therapeutics Market include:
Key companies developing therapies for Rheumatoid Arthritis are – Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, RedHill Biopharma, 4D Pharma, CV6 Therapeutics, VYNE Therapeutics, MyMD Pharmaceuticals, Brickell Biotech Inc, Worg Pharmaceuticals, Almirall, Standigm, Metrion Biosciences, Jnana Therapeutics, Silo Pharma, SFA Therapeutics, Neutrolis Therapeutics, Ahead Therapeutics, Fresenius Kabi, Kidswell Bio, BioXpress Therapeutics, CinnaGen, Alvotech, Hetero Biopharma, Shanghai Henlius Biotech, Cadila Pharmaceuticals, Innovent Biologics, Torrent Pharmaceuticals, Emcure Pharmaceuticals, mAbxience, Shanghai Junshi Biosciences, Enosi Therapeutics, and others.
Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:
LABP-69: Landos Biopharma
ON 104: OncoOne
14-3-3 zeta Protein-based vaccine: The University of Toledo
TJ003234: I-Mab Biopharma Co. Ltd.
Guizhi Shaoyao Zhimu Decoction: Beijing University of Chinese Medicine
TCK-276: Teijin Pharma
ABX464: Abivax S.A.
Hemay007: Hemay Pharmaceutical
AP1189: SynAct Pharma Aps
Trivalent Chromium: Alexandria University
Olokizumab: R-Pharm
MabionCD20: Mabion
Otilimab: GlaxoSmithKline
Get a Free Sample PDF Report to know more about Rheumatoid Arthritis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight
Rheumatoid Arthritis Pipeline Analysis:
The Rheumatoid Arthritis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis Treatment.
Rheumatoid Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rheumatoid Arthritis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis pipeline report to learn more about the emerging Rheumatoid Arthritis therapies
Rheumatoid Arthritis Pipeline Market Drivers
Rising prevalence of arthritis worldwide
Acceptance of biosimilars for treatment of Rheumatoid Arthritis
Rheumatoid Arthritis Pipeline Market Barriers
High cost of biologics
Lack of resources in underdeveloped nations
Scope of Rheumatoid Arthritis Pipeline Drug Insight
Coverage: Global
Key Rheumatoid Arthritis Companies: Landos Biopharma, OncoOne, zeta Protein-based vaccine: The University of Toledo, I-Mab Biopharma Co. Ltd., Beijing University of Chinese Medicine, Teijin Pharma, Hemay Pharmaceutical, SynAct Pharma Aps, Alexandria University, R-Pharm, Mabion, GlaxoSmithKline, and others
Key Rheumatoid Arthritis Therapies: LABP-69, ON 104, 14-3-3, TJ003234, Guizhi Shaoyao Zhimu Decoction, TCK-276, ABX464: Abivax S.A., Hemay007, AP1189, Trivalent Chromium, Olokizumab, MabionCD20, Otilimab, and others
Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies
Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers
Request for Sample PDF Report for Rheumatoid Arthritis Pipeline Assessment and clinical trials
Table of Contents
1
Rheumatoid Arthritis Report Introduction
2
Rheumatoid Arthritis Executive Summary
3
Rheumatoid Arthritis Overview
4
Rheumatoid Arthritis- Analytical Perspective In-depth Commercial Assessment
5
Rheumatoid Arthritis Pipeline Therapeutics
6
Rheumatoid Arthritis Late Stage Products (Phase II/III)
7
Rheumatoid Arthritis Mid Stage Products (Phase II)
8
Rheumatoid Arthritis Early Stage Products (Phase I)
9
Rheumatoid Arthritis Preclinical Stage Products
10
Rheumatoid Arthritis Therapeutics Assessment
11
Rheumatoid Arthritis Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Rheumatoid Arthritis Key Companies
14
Rheumatoid Arthritis Key Products
15
Rheumatoid Arthritis Unmet Needs
16
Rheumatoid Arthritis Market Drivers and Barriers
17
Rheumatoid Arthritis Future Perspectives and Conclusion
18
Rheumatoid Arthritis Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Rheumatoid Arthritis drugs and therapies
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis
